Spending on HCV medications much higher in the US than Canada
- PDF / 166,958 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 71 Downloads / 155 Views
1
Spending on HCV medications much higher in the US than Canada Spending on direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection is substantial in the US and in Canada, but the US spends substantially more per capita on these antivirals despite similar rates of HCV infection in these two countries. These are the main findings of a retrospective cross-sectional study that compared drug expenditures on DAAs in the US and Canada between January 2014 through June 2018 using prescription claims from community pharmacies and outpatient dispensing obtained from the IQVIA National Sales Perspectives database for the US and the Geographic Prescription Monitor database for Canada. Over the 4.5-year study period, the total expenditure on HCV medications was $US59.7 billion in the US and $2.8 billion in Canada (year 2017 values). Although the rates of HCV infection are similar between the two countries, population-adjusted HCV medication costs over the entire study period were substantially higher in the US ($1 million per 100 000 population), compared with Canada (0.4 million per 100 000 population). The analysis of the trends in costs over time showed that population-adjusted annual medication costs between 2014 and 2017 ranged from $0.8 million to $1.4 million per 100 000 population in the US and from $0.1 million to $0.5 million per 100 000 population in Canada. "These findings highlight the differences in both the reimbursement utilization policy for HCV treatments and the major differences in drug pricing policies," note the researchers. Shakeri A, et al. Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. Value in Health 23: 1137-1141, No. 9, Sep 2020
1173-5503/20/0863-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803504701
PharmacoEconomics & Outcomes News 3 Oct 2020 No. 863
Data Loading...
